Refractory GERD symptoms

Refractory GERD can be associated with a variety of uncomfortable reflux symptoms. Fortunately, they are manageable with the right treatment.

Refractory GERD symptoms may include

Heartburn—Burning sensation under the breastbone
Regurgitation—The return of partly digested food or liquid from the stomach to the mouth or esophagus
Chest pain—Burning pain in the chest or upper abdomen. This pain may feel somewhat like heart pain
Cough—Often happens along with heartburn and regurgitation
Hoarseness—Stomach acid enters into the esophagus and irritates the vocal cords, causing a person’s voice to weaken
Difficulty swallowing—Regurgitation of stomach acid can cause damage to the esophagus, which can make it hard for some people to swallow food and liquids
Sleep disturbances—People with refractory GERD may wake up during the night because of discomfort. Symptoms may also get worse when a person is lying down

If you are experiencing any of these symptoms, talk to your healthcare professional. He or she can help determine if you have refractory GERD and prescribe the right medicine for you.

Consider Metozolv ODT for refractory GERD treatment

Metozolv ODT, an orally disintegrating tablet, treats the problems that cause refractory GERD symptoms.1 Talk to your healthcare professional to learn more about Metozolv ODT for refractory GERD treatment.

Is Metozolv ODT right for you? Discover valuable tools and resources about diabetic gastroparesis, refractory GERD, and Metozolv ODT Learn diet tips that may help improve symptoms of refractory GERD

Reference: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.

IMPORTANT SAFETY INFORMATION

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms; neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience withdrawal symptoms after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Please see accompanying full Prescribing Information for Metozolv ODT, including BOXED WARNING.